+ A
A -
AFP
Washington
Although none of the coronavirus vaccines under development has proved its efficacy yet in clinical trials, at least 5.7 billion doses have been pre-ordered around the world.
First shipments of a COVID-19 vaccine created by Western laboratories have often been snapped up by the United States.
Five vaccines -- three Western and two Chinese -- are in Phase 3 efficacy trials involving thousands of people.
As research laboratories around the world race to develop a vaccine, manufacturers have received financing to help them prepare to have millions of doses ready to administer in 2021 or even before the end of the year.
Oxford University, working with the Swedish-British pharmaceutical group AstraZeneca, hopes to have results by September while the US biotech company Moderna, partnering with the US National Institutes of Health (NIH), is aiming for the end of the year, possibly November.
- US: 700 million doses -President Donald Trump has launched “Operation Warp Speed” in a bid to develop, manufacture and distribute a COVID-19 vaccine to all Americans by January 2021.
Hundreds of millions of dollars have been directed to vaccine developers including nearly $500 million to Johnson & Johnson at the end of March.
The United States has allocated funding to more companies than other nation in the hope that one of them will come up with the vaccine to counter the highly contagious virus.
So far, Washington has handed out at a total of least 9.4 billion dollars to seven vaccine developers and signed manufacturing contracts with five of them to provide 700 million doses.
The companies involved are: Johnson & Johnson, Moderna, Oxford/AztraZeneca, Novavax, Pfizer/BioNTech, Sanofi/GSK, Merck Sharp and Dohme.
Washington
Although none of the coronavirus vaccines under development has proved its efficacy yet in clinical trials, at least 5.7 billion doses have been pre-ordered around the world.
First shipments of a COVID-19 vaccine created by Western laboratories have often been snapped up by the United States.
Five vaccines -- three Western and two Chinese -- are in Phase 3 efficacy trials involving thousands of people.
As research laboratories around the world race to develop a vaccine, manufacturers have received financing to help them prepare to have millions of doses ready to administer in 2021 or even before the end of the year.
Oxford University, working with the Swedish-British pharmaceutical group AstraZeneca, hopes to have results by September while the US biotech company Moderna, partnering with the US National Institutes of Health (NIH), is aiming for the end of the year, possibly November.
- US: 700 million doses -President Donald Trump has launched “Operation Warp Speed” in a bid to develop, manufacture and distribute a COVID-19 vaccine to all Americans by January 2021.
Hundreds of millions of dollars have been directed to vaccine developers including nearly $500 million to Johnson & Johnson at the end of March.
The United States has allocated funding to more companies than other nation in the hope that one of them will come up with the vaccine to counter the highly contagious virus.
So far, Washington has handed out at a total of least 9.4 billion dollars to seven vaccine developers and signed manufacturing contracts with five of them to provide 700 million doses.
The companies involved are: Johnson & Johnson, Moderna, Oxford/AztraZeneca, Novavax, Pfizer/BioNTech, Sanofi/GSK, Merck Sharp and Dohme.
